{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T17:56:02Z","timestamp":1792518962642,"version":"4.5.0"},"reference-count":44,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,20]],"date-time":"2024-07-20T00:00:00Z","timestamp":1721433600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.jcf.2024.07.012","type":"journal-article","created":{"date-parts":[[2024,7,23]],"date-time":"2024-07-23T20:59:16Z","timestamp":1721768356000},"page":"950-958","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["The clinical effectiveness of elexacaftor\/tezacaftor\/ivacaftor (ETI) for people with CF without a F508del variant: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-1851-9734","authenticated-orcid":false,"given":"Daniel","family":"Lupas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8610-852X","authenticated-orcid":false,"given":"Frank Y.","family":"Chou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Abdullah Al","family":"Hakani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ishita","family":"Kuthiala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arjuna","family":"Srikrishnaraj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5645-5202","authenticated-orcid":false,"given":"Naomi","family":"Potter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1785-3870","authenticated-orcid":false,"given":"Bradley S.","family":"Quon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4922","key":"10.1016\/j.jcf.2024.07.012_bib0001","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1126\/science.2475911","article-title":"Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA","volume":"245","author":"Riordan","year":"1989","journal-title":"Science"},{"issue":"4922","key":"10.1016\/j.jcf.2024.07.012_bib0002","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1126\/science.2772657","article-title":"Identification of the cystic fibrosis gene: chromosome walking and jumping","volume":"245","author":"Rommens","year":"1989","journal-title":"Science"},{"issue":"4922","key":"10.1016\/j.jcf.2024.07.012_bib0003","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1126\/science.2570460","article-title":"Identification of the cystic fibrosis gene: genetic analysis","volume":"245","author":"Kerem","year":"1989","journal-title":"Science"},{"issue":"7","key":"10.1016\/j.jcf.2024.07.012_bib0004","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1016\/0092-8674(93)90353-R","article-title":"Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis","volume":"73","author":"Welsh","year":"1993","journal-title":"Cell"},{"key":"10.1016\/j.jcf.2024.07.012_bib0005","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1146\/annurev-med-042921-021447","article-title":"Cystic fibrosis modulator therapies","volume":"74","author":"Jia","year":"2023","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.jcf.2024.07.012_bib0006","unstructured":"Zolin A.O.A., Jung A., van Rens J., et al. ECFSPR Annual Report 2021. 2023."},{"key":"10.1016\/j.jcf.2024.07.012_bib0007","unstructured":"CFF. FDA Approves Expansion of Modulators for People With Certain Rare Mutations. 2020 [Available from: https:\/\/www.cff.org\/news\/2020-12\/fda-approves-expansion-modulators-people-certain-rare-mutations."},{"key":"10.1016\/j.jcf.2024.07.012_bib0008","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.jcf.2024.07.012_bib0009","unstructured":"Covidence systematic review software, Veritas Health Innovation, Melbourne, Australia. 2023. Available at: www.covidence.org."},{"key":"10.1016\/j.jcf.2024.07.012_bib0010","unstructured":"National Heart Lung, and Blood Institute. Study quality assessment tools. 2021. Available at: www.nhlbi.nih.gov\/health-topics\/study-quality-assessment-tools."},{"key":"10.1016\/j.jcf.2024.07.012_bib0011","series-title":"JBI Manual for Evidence Synthesis","article-title":"Chapter 7: systematic reviews of etiology and risk","author":"Moola","year":"2020"},{"issue":"10","key":"10.1016\/j.jcf.2024.07.012_bib0012","first-page":"2127","article-title":"Methodological quality of case series studies: an introduction to the JBI critical appraisal tool","volume":"18","author":"Munn","year":"2020","journal-title":"JBI Evid Synth"},{"key":"10.1016\/j.jcf.2024.07.012_bib0013","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02437-2022","article-title":"The french compassionate program of elexacaftor-tezacaftor-ivacaftor in people with cystic fibrosis with advanced lung disease and no F508del CFTR variant","author":"Burgel","year":"2023","journal-title":"Eur Respir J"},{"issue":"6","key":"10.1016\/j.jcf.2024.07.012_bib0014","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/j.jcf.2023.06.001","article-title":"Clinical and functional efficacy of elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis carrying the N1303K mutation","volume":"22","author":"Sadras","year":"2023","journal-title":"J Cyst Fibros"},{"issue":"3","key":"10.1016\/j.jcf.2024.07.012_bib0015","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.jcf.2022.10.011","article-title":"Treatment effects of Elexacaftor\/Tezacaftor\/Ivacaftor in people with CF carrying non-F508del mutations","volume":"22","author":"Livnat","year":"2023","journal-title":"J Cyst Fibros"},{"issue":"1","key":"10.1016\/j.jcf.2024.07.012_bib0016","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1002\/ppul.26713","article-title":"The effectiveness of CFTR modulators in people with CF and rare mutations: a real-world study","volume":"59","author":"Hanger","year":"2024","journal-title":"Pediatr Pulmonol"},{"issue":"1","key":"10.1016\/j.jcf.2024.07.012_bib0017","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01959-2023","article-title":"Gathering real-world compassionate data to expand eligibility for elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis with N1303K or other rare CFTR variants: a viewpoint","volume":"63","author":"Burgel","year":"2024","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jcf.2024.07.012_bib0018","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcf.2024.02.008","article-title":"Clinical efficacy of CFTR modulator therapy in people with cystic fibrosis carrying the I1234V mutation","author":"Aluma","year":"2024","journal-title":"J Cyst Fibros"},{"issue":"3","key":"10.1016\/j.jcf.2024.07.012_bib0019","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.jcf.2020.07.003","article-title":"CFTR modulator therapy for cystic fibrosis caused by the rare c.3700A>G mutation","volume":"20","author":"Phuan","year":"2021","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2024.07.012_bib0020","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1153656","article-title":"Differential effects of ELX\/TEZ\/IVA on organ-specific CFTR function in two patients with the rare CFTR splice mutations c.273+1G>A and c.165-2A>G","volume":"14","author":"Pallenberg","year":"2023","journal-title":"Front Pharmacol"},{"issue":"15","key":"10.1016\/j.jcf.2024.07.012_bib0021","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241512365","article-title":"Personalized CFTR modulator therapy for G85E and N1303K homozygous patients with cystic fibrosis","volume":"24","author":"Graeber","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jcf.2024.07.012_bib0022","article-title":"Elexacaftor-Tezacaftor-Ivacaftor in 2 cystic fibrosis adults homozygous for M1101K with end-stage lung disease","volume":"46","author":"Leung","year":"2023","journal-title":"Respir Med Case Rep"},{"issue":"1","key":"10.1016\/j.jcf.2024.07.012_bib0023","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00746-2023","article-title":"Cystic fibrosis airway inflammation enables elexacaftor\/tezacaftor\/ivacaftor-mediated rescue of N1303K CFTR mutation","volume":"10","author":"Gentzsch","year":"2024","journal-title":"ERJ Open Res"},{"key":"10.1016\/j.jcf.2024.07.012_bib0024","article-title":"Elexacaftor\/Tezacaftor\/Ivacaftor effectiveness in N1303K variant in adult people with cystic fibrosis","author":"Goncalves Martynychen Canan","year":"2024","journal-title":"Arch Bronconeumol"},{"key":"10.1016\/j.jcf.2024.07.012_bib0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.pulmoe.2024.03.001","article-title":"Efficacy of elexacaftor-tezacaftor-ivacaftor in portuguese adolescents and adults with cystic fibrosis carrying non-F508del variants","author":"Pinto","year":"2024","journal-title":"Pulmonology"},{"issue":"10","key":"10.1016\/j.jcf.2024.07.012_bib0026","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1164\/rccm.202101-0090LE","article-title":"Elexacaftor\/Tezacaftor\/Ivacaftor improved clinical outcomes in a patient with N1303K-CFTR based on in vitro experimental evidence","volume":"204","author":"Huang","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"10.1016\/j.jcf.2024.07.012_bib0027","first-page":"396","article-title":"CFTR Modulator Therapy in an Individual With Cystic Fibrosis Caused by a N1303K CFTR Variant and Infected With Mycobacterium abscessus","volume":"27","author":"Elson","year":"2022","journal-title":"J Pediatr Pharmacol Ther"},{"key":"10.1016\/j.jcf.2024.07.012_bib0028","article-title":"Clinical efficacy of elexacaftor-tezacaftor-ivacaftor in an adolescent with homozygous G85E cystic fibrosis","volume":"40","author":"Stekolchik","year":"2022","journal-title":"Respir Med Case Rep"},{"issue":"1","key":"10.1016\/j.jcf.2024.07.012_bib0029","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00770-2023","article-title":"Organoid-guided synergistic treatment of minimal function CFTR mutations with CFTR modulators, roflumilast and simvastatin: a personalised approach","volume":"63","author":"Spelier","year":"2024","journal-title":"Eur Respir J"},{"issue":"5","key":"10.1016\/j.jcf.2024.07.012_bib0030","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25052770","article-title":"Comprehensive assessment of CFTR Modulators' therapeutic efficiency for N1303K variant","volume":"25","author":"Efremova","year":"2024","journal-title":"Int J Mol Sci"},{"issue":"5","key":"10.1016\/j.jcf.2024.07.012_bib0031","doi-asserted-by":"crossref","first-page":"e26955","DOI":"10.1016\/j.heliyon.2024.e26955","article-title":"Response to Elexacaftor\/Tezacaftor\/Ivacaftor in people with cystic fibrosis with the N1303K mutation: case report and review of the literature","volume":"10","author":"Tupayachi Ortiz","year":"2024","journal-title":"Heliyon"},{"key":"10.1016\/j.jcf.2024.07.012_bib0032","doi-asserted-by":"crossref","DOI":"10.1002\/ppul.26997","article-title":"Clinical effectiveness of elexacaftor\/tezacaftor\/ivacaftor in a man with A559T and 3120+1G>CFTR variants","author":"Mitchell","year":"2024","journal-title":"Pediatr Pulmonol"},{"issue":"10212","key":"10.1016\/j.jcf.2024.07.012_bib0033","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial","volume":"394","author":"Heijerman","year":"2019","journal-title":"Lancet"},{"issue":"19","key":"10.1016\/j.jcf.2024.07.012_bib0034","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single Phe508del Allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcf.2024.07.012_bib0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcf.2024.02.006","article-title":"In vitro modulator responsiveness of 655 CFTR variants found in people with cystic fibrosis","author":"Bihler","year":"2024","journal-title":"J Cyst Fibros"},{"issue":"3","key":"10.1016\/j.jcf.2024.07.012_bib0036","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1056\/NEJMoa1409547","article-title":"Lumacaftor-ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR","volume":"373","author":"Wainwright","year":"2015","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.jcf.2024.07.012_bib0037","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1056\/NEJMoa1709846","article-title":"Tezacaftor-ivacaftor in patients with cystic fibrosis homozygous for Phe508del","volume":"377","author":"Taylor-Cousar","year":"2017","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.jcf.2024.07.012_bib0038","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S2213-2600(14)70132-8","article-title":"A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial","volume":"2","author":"Boyle","year":"2014","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jcf.2024.07.012_bib0039","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1186\/1756-0500-7-264","article-title":"The clinical case report: a review of its merits and limitations","volume":"7","author":"Nissen","year":"2014","journal-title":"BMC Res Notes"},{"issue":"1","key":"10.1016\/j.jcf.2024.07.012_bib0040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1513\/AnnalsATS.201708-668PS","article-title":"The U.S. Food and drug administration's experience with ivacaftor in cystic fibrosis. Establishing efficacy using in vitro data in lieu of a clinical trial","volume":"15","author":"Durmowicz","year":"2018","journal-title":"Ann Am Thorac Soc."},{"issue":"5","key":"10.1016\/j.jcf.2024.07.012_bib0041","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/j.jcf.2020.05.012","article-title":"Cystic fibrosis drug trial design in the era of CFTR modulators associated with substantial clinical benefit: stakeholders' consensus view","volume":"19","author":"De Boeck","year":"2020","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2024.07.012_bib0042","doi-asserted-by":"crossref","unstructured":"Solomon G.M., Linnemann R., Rich R., Streby A., Buehler B., Hunter E., et al. Elexacaftor-Tezacaftor-Ivacaftor Improves Clinical Outcomes in Individuals with CF Encoding N1303K CFTR. (Posted March 8, 2024). Available at: SSRN: https:\/\/ssrn.com\/abstract=4745080 or http:\/\/dx.doi.org\/10.2139\/ssrn.4745080.","DOI":"10.2139\/ssrn.4745080"},{"key":"10.1016\/j.jcf.2024.07.012_bib0043","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.jclinepi.2017.08.010","article-title":"Living systematic review: 1. Introduction-the why, what, when, and how","volume":"91","author":"Elliott","year":"2017","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.jcf.2024.07.012_bib0044","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1016\/j.jpeds.2016.09.063","article-title":"Applying cystic fibrosis transmembrane conductance regulator genetics and CFTR2 data to facilitate diagnoses","volume":"181S","author":"Sosnay","year":"2017","journal-title":"J Pediatr"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199324007963?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199324007963?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T07:14:01Z","timestamp":1788246841000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199324007963"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":44,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S1569199324007963"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2024.07.012","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The clinical effectiveness of elexacaftor\/tezacaftor\/ivacaftor (ETI) for people with CF without a F508del variant: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2024.07.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society.","name":"copyright","label":"Copyright"}]}}